Tracks nemolizumab use in adolescents and adults with atopic dermatitis
Observes how nemolizumab works for moderate-to-severe atopic dermatitis in routine care.
Plain-language title generated from the registry record
Registry title: Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Key facts
- Where
- Ahaus, Augsburg, Berlin, Bernau bei Berlin, Bielefeld, Buxtehude, Erlangen, Gladbeck, Großenhain, Haslach im Kinzigtal, Hersbruck, Karlsruhe, Koblenz, Langenau, Lübeck, Mainz, Oberursel, Oranienburg, Pforzheim, Quedlinburg, Regensburg, and Remscheid, GermanySee the 25 sites
Where in Germany
- AhausAhaus, GermanyTaking people
- AugsburgAugsburg, GermanyTaking people
- AugsburgAugsburg, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- Bernau bei BerlinBernau bei Berlin, GermanyTaking people
- BielefeldBielefeld, GermanyTaking people
- BuxtehudeBuxtehude, GermanyTaking people
- ErlangenErlangen, GermanyTaking people
- GladbeckGladbeck, GermanyTaking people
- GroßenhainGroßenhain, GermanyTaking people
- Haslach im KinzigtalHaslach im Kinzigtal, GermanyTaking people
- HersbruckHersbruck, GermanyTaking people
- KarlsruheKarlsruhe, GermanyTaking people
- KoblenzKoblenz, GermanyTaking people
- LangenauLangenau, GermanyTaking people
- LübeckLübeck, GermanyTaking people
- MainzMainz, GermanyTaking people
- OberurselOberursel, GermanyTaking people
- OranienburgOranienburg, GermanyTaking people
- PforzheimPforzheim, GermanyTaking people
- QuedlinburgQuedlinburg, GermanyTaking people
- RegensburgRegensburg, GermanyTaking people
- RemscheidRemscheid, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Galderma R&D
- Trial code
- NCT06988605
- Record updated
- 13 March 2026
- Original description
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.Read full original descriptionShow less
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Inclusion: Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®); Adolescent and adult participants aged >=12 years with moderate-to-severe AD; Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Exclusion: Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline; Participants who received nemolizumab previously; Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label; Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.